Novel Oncology Therapeutics: Targeting Hope
On Demand Course

Premier Sponsor

**AGENDA**

<table>
<thead>
<tr>
<th>Session Duration</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 90 minutes       | Lecture Series – The Expanding Clinical Role of Cancer Immunotherapy  
• Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy  
• Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade  
• Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology.  
• Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions  
• Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan |
| 60 minutes       | Interactive Discussion – Cancer Immunotherapy  
• Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy.  
• Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade  
• Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology.  
• Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions  
• Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan  
Moderator: Dr. Joelle Fenger |
## AGENDA

<table>
<thead>
<tr>
<th>Session Duration</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 60 minutes       | **Lecture Series – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations** | • Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics  
• Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients  
• Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer  
• Understand the difference between FDA-approved and 503A and 503B compounded products  
• Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Luke Wittenburg, Dr. Heather Gardner, Dr. Lauren Forsythe |
| 60 minutes       | **Interactive Discussion – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations** | • Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics  
• Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients  
• Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer  
• Understand the difference between FDA-approved and 503A and 503B compounded products  
• Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Luke Wittenburg, Dr. Heather Gardner, Dr. Lauren Forsythe  
Moderator: Dr. Sue Lana |
# AGENDA

<table>
<thead>
<tr>
<th>Session Duration</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 30 minutes       | **Immune Checkpoint Inhibitors: Oh, the Places (We Hope!) You’ll Go – Presented by Merck**  
  - Understand the pros and cons of several potential biomarkers for successful use of immune checkpoint inhibition therapy and review what we currently know about these biomarkers in veterinary medicine.  
  - Gain familiarity with the indications, administration, and safety profile of gilvetmab. | Dr. Laura Greene |
| 90 minutes       | **Lecture Series – Targeted Therapies: Clinical Applications, Combinations and Clinicians’ Experiences**  
  - Become familiar with newer targeted therapies available in veterinary oncology  
  - Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers  
  - Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies  
  - Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum |
| 60 minutes       | **Interactive Discussion – Targeted Therapies: Clinical Applications, Combinations and Clinicians’ Experiences**  
  - Become familiar with newer targeted therapies available in veterinary oncology  
  - Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers  
  - Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies  
  - Incorporate information discussed in this session into your clinical practice and client discussions | Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum  
  **Moderator:** Dr. Jenna Burton |